On April 8, 2021, Kaleido Biosciences, Inc. (the "Company") delivered formal notice to The Nasdaq Stock Market, Inc. that the Company intends to voluntarily delist its common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Global Select Stock Market ("Nasdaq") in connection with the Company's cessation of all operations as described in Item 8.01 below.
The Company expects to file a Form 25 with the Securities and Exchange Commission (the "SEC") on or about April 18, 2022 to effect the voluntary delisting of the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and that the delisting will be effective on or about April 28, 2022 - ten days after the filing of the Form 25. Following the effectiveness of the delisting, it intends to file a Form 15 with the SEC to suspend the Company's Exchange Act reporting obligations.
https://www.marketscreener.com/quote/stock/KALEIDO-BIOSCIENCES-INC-55288611/news/KALEIDO-BIOSCIENCES-INC-Notice-of-Delisting-or-Failure-to-Satisfy-a-Continued-Listing-Rule-or-St-40004410/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.